PowerPoint Presentation

[Audio] Aqsa Bibi is researching the effect of Geniposide on Multiple Sclerosis and its potential to alter the S100b-RAGE Pathway at Shandong Normal University (SDNU), under the supervision of Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv. The project is scheduled for completion by 16 December 2023 and consists of research background, objectives, technical routes, research content, results, and future work. This research will help us to gain further insight into the effects of Geniposide on Multiple Sclerosis..

[Audio] Aqsa Bibi is undertaking research at Shandong Normal University on the effect of Geniposide on Multiple Sclerosis via the S100b-RAGE Pathway. Her aim is to evaluate Geniposide's potential to slow the progression of the disease due to its anti-inflammatory properties. She will be focussing on the effect of this compound on the S100b-RAGE Pathway, which is believed to be a major contributor to the development of Multiple Sclerosis. Aqsa is being supervised by Professors Guiwen Yang and Cui Lv, and plans to complete her research by 16 December 2023..

[Audio] Aqsa Bibi graduated from the University of Karachi in 2020 with a degree in Biomedical Sciences. She is currently leading a research project on the effect of Geniposide on Multiple Sclerosis through the S100b-RAGE Pathway at Shandong Normal University, supervised by Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv. The objective of the research is to explore the potential of Geniposide as a targeted therapeutic treatment for MS, by analysing its effect on the S100b-RAGE Pathway. With the ambitious goal of reducing the prevalence of MS worldwide, this research is expected to have a major impact on MS diagnosis, prognosis, and treatments. The international collaboration between Shandong Normal University and the University of Karachi to tackle the growing prevalence of Multiple Sclerosis is a significant accomplishment. The research is scheduled for completion by 16 December 2023..

[Audio] Aqsa Bibi is researching the influence of the natural compound Geniposide on Multiple Sclerosis, an autoimmune disorder with persistent, debilitating symptoms. Her team is investigating how Geniposide may interact with the S100b-RAGE Pathway, which is known to have a significant impact on the development of MS. Based at Shandong Normal University, Aqsa is working with two renowned professors, Dr. Guiwen Yang and Dr. Cui Lv, with the aim of finishing the project by December 2023. Through this research, Aqsa hopes to bring a better understanding of the root causes of Multiple Sclerosis..

[Audio] Aqsa Bibi is conducting research at Shandong Normal University that aims to investigate the potential effects of the drug, Geniposide, on Multiple Sclerosis through the S100b-RAGE Pathway. This study, supervised by Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv, will run until 16 December 2023. Currently, the treatment of Multiple Sclerosis by western medicines relies on neuroprotection and suppression of inflammation. However, drugs approved by the FDA for treatment of MS are often expensive, have potential side effects and toxic, and can be less effective. Aqsa Bibi's research may provide a promising alternative for the treatment of Multiple Sclerosis through the use of Geniposide. Thus, the outcome of this study is of great potential significance for the future of MS treatment..

[Audio] Aqsa Bibi is part of an ongoing research project into the potential of traditional Chinese medicine to treat Multiple Sclerosis. Her research focuses on the effect of Geniposide, an active ingredient found in some Traditional Chinese Medicines, on Multiple Sclerosis through the S100b-RAGE Pathway. Geniposide has shown to have anti-inflammatory effects and to reduce the expression of pro-inflammatory cytokines. With the guidance of her supervisors, Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv, Aqsa Bibi is studying the effect Geniposide has on Multiple Sclerosis, with the aim to complete the project by December 2023. This study brings us one step closer to understanding how Traditional Chinese Medicine can contribute to treating complex neurological diseases..

[Audio] Today I will be discussing the research being conducted on Geniposide and its potential therapeutics. Geniposide is an iridoid glycoside extracted from Gardenia jasminoides fruit, known to inhibit the production of inflammation-related enzymes and inflammatory factors. It has also been shown to have neuroprotective effects in brain disease models. In addition, it has been shown to have effects on proliferation and differentiation of CD4+ T cells. Our group recently discovered that geniposide can reduce the risk of Alzheimer's disease by blocking the interaction between amyloid beta(Aβ) and the receptor for advanced glycation end products (RAGE). It was found that Aβ-induced RAGE activation led to microglia and inflammatory response in mice with AD disease model, and that this was accompanied by improved cognitive functions in mice. Currently, Aqsa Bibi is investigating the effect of Geniposide on Multiple Sclerosis through the S100b-RAGE Pathway at Shandong Normal University, under the supervision of Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv, with a completion date of 16 December 2023. The research aims to further explore the potential benefits of Geniposide on Multiple Sclerosis and other cardiovascular disease models. We are optimistic about the results of this research and its potential implications on the treatment of Multiple Sclerosis..

[Audio] Aqsa Bibi is investigating the impact of Geniposide on Multiple Sclerosis through the S100b-RAGE Pathway at Shandong Normal University in partnership with Dr. Guiwen Yang and Dr. Cui Lv, with a projected conclusion date of December 16th, 2023. She is evaluating various aspects involved in this process, such as the Anti-RAGE antibody, the flRAGE V-Domain, the ADAM-IO C1-Domain, the C2-Domain, the Cytoplasmic tail, the sRAGEi and sRAGE, the esRAGE, sloos -1MGB1, and GE 1 TGa. Her research also includes examining inflammatory components like Angiogenesis, RAGE expression, and TIRAP; DIAPHI, Ras and other ligands; Clq and small molecule inhibitors; Racl/Cdc42; P13K; NADPH oxidase; AKT; RO; GSK-3ß; NE-KB; MEK; ERKI/MKK6; MKK4/7; SAPK/JNK; Egr-1; AP-I; and STAT3. Additionally, she is assessing the influence of these aspects on gene expression, migration, proliferation, and oxidative stress..

[Audio] Aqsa Bibi is conducting research at Shandong Normal University under the supervision of Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv with the aim of determining how geniposide could be used to treat multiple sclerosis. The experiments involve investigating the effect of geniposide on multiple sclerosis through the S100b-RAGE pathway, as well as exploring the correlation of ligands with other conditions such as hypertension, diabetes, renal disease, atherosclerosis, tumors, and cognitive dysfunction. This could also have implications for Alzheimer's disease. The research is expected to be concluded by 16 December 2023 and it is hoped that it will yield benefits for those living with multiple sclerosis..

[Audio] Aqsa Bibi is conducting research at Shandong Normal University on the effects of geniposide on multiple sclerosis via the S100b-RAGE pathway. The research is supervised by Professors Guiwen Yang and Cui Lv, with an expected completion by 16 December 2023. Aqsa is examining how RAGE ligand could trigger an inflammatory response in the central nervous system in diseases like multiple sclerosis. She is also looking into how RAGE, S100b, NaiveCD4+T migration, HMGB1 and advanced glycation endproducts may be related to the effects of geniposide on multiple sclerosis. Through this research, Aqsa is looking to gain more insight into multiple sclerosis and its potential treatment options..

[Audio] Aqsa Bibi, at Shandong Normal University (SDNU), is studying the impact of Geniposide on Multiple Sclerosis, focusing on the S100b-RAGE pathway. Through her research, she aims to understand the mechanism of pathogenesis of Multiple Sclerosis, as well as its relation to β-amyloid plaques and neuroinflammation. With a deeper insight on these connections, it is then possible to further investigate potential treatments to lessen the cognitive decline caused by the disease and fortify the neuroprotection against Alzheimer's Disease..

[Audio] Aqsa Bibi, a student at Shandong Normal University (SDNU), is conducting research on the effect of geniposide on Multiple Sclerosis. Under the supervision of Professors Dr. Guiwen Yang and Dr. Cui Lv, the project is expected to be finished by December 2023. The possibility of geniposide being an effective therapy for Multiple Sclerosis has not yet been explored. In order to gain a better understanding of how S100b affects naive CD4+ T cells, research must be done to detect the increased S100b levels in MS patient serum. Moreover, the role of the RAGE pathway in CD4+ T cells and MS pathogenesis still remains unknown. Dedicated to finding possible treatments for MS, Aqsa Bibi's research has the potential of making a considerable contribution to this field of study..

[Audio] Aqsa Bibi is conducting a research project at Shandong Normal University to explore the impact of Geniposide on Multiple Sclerosis through the S100b-RAGE Pathway. The project is being supervised by Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv with a due date of 16 December 2023. Its objectives include evaluating the effect of Geniposide on an EAE mouse model, understanding the molecular mechanism of Geniposide in EAE by modifying CD4+ T cells through the S100b-RAGE pathway, and investigating the part of the S100b-RAGE pathway on proliferation, migration and differentiation of CD4+ T cells..

[Audio] Aqsa Bibi, a student of Shandong Normal University, is researching the effect of Geniposide on Multiple Sclerosis through the S100b-RAGE Pathway, with a completion date of 16 December 2023. Supervised by Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv, the geniposide selected in this project has great potential for treatment of this neurological disorder, and, if successful, could lay a theoretical foundation for the development of related drugs in the future. It may also help in deepening our understanding of the mechanism of RAGE in multiple sclerosis, and, consequently, provide new ideas for the treatment of this disease. Data generated by the research has the potential to lead to further theoretical innovations..

[Audio] Aqsa Bibi is conducting research at Shandong Normal University to examine the impact of Geniposide on Multiple Sclerosis through the S100b-RAGE Pathway. This research is being supervised by Professors Dr. Guiwen Yang and Dr. Cui Lv and will involve constructing an EAE mouse model and isolating CD4+ T cells from blood, lymph nodes, and spleen. It will also study the effect of the pathway on naïve CD4+ T cells, the impact of geniposide intervention, and the CD4+ T cell infiltration of the spinal cord. The outcome will help confirm the role of RAGE pathways for the treatment of MS, understand geniposide mechanisms, and detect RAGE, S100b, and NFkB in the spinal cord. The work is expected be completed on 16 December 2023..

[Audio] Aqsa Bibi is conducting research to examine the potential of Geniposide in treating Multiple Sclerosis, under the supervision of Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv and is expected to be completed on 16 December 2023. To investigate the protective effect of Geniposide, a MoG polypeptide induced EAE model was utilized. Results demonstrated a decrease in the body weight of mice after immunization and an improved neurological function score, suggesting the potential therapeutic effects of Geniposide for the treatment of Multiple Sclerosis..

[Audio] Aqsa Bibi is conducting research at Shandong Normal University on the effects of Geniposide on Multiple Sclerosis via the S100b-RAGE Pathway, under the guidance of Professors Guiwen Yang and Cui Lv, with an expected completion date of December 16th 2023. Figure 2 in this slide shows the EAE mouse incidence-time curve, where statistically significant differences in the incidence-time curve of mice injected with Geniposide compared to the non-induced group and EAE+DD water group are shown, as shown by the asterisk indicating a p value of less than 0.05. The number of mice in each group was 10..

[Audio] Aqsa Bibi is conducting remarkable research at Shandong Normal University under the guidance of Professors Guiwen Yang and Cui Lv. Her project focuses on the potential impact of Geniposide on Multiple Sclerosis and intends to analyze its influence on the S100b-RAGE Pathway. The target date for completion of her research project is 16 December 2023. Figure 4 illustrates the alterations in the proportions of different cell subpopulations in the spleen in response to Geniposide. It exhibits noteworthy shifts in the portion of CD44+ IFN-γ+ T cells among CD4+ T cells, the ratio of CD44+ IL-17+ T cells to CD4+ T cells, the proportion of CD44+ GM-CSF+ T cells among CD4+ T cells and the proportion of CD25+ Foxp3+ T cells among CD4+ T cells. These results indicate that Geniposide may have a beneficial effect on Multiple Sclerosis..

[Audio] Aqsa Bibi, supervised by Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv, is conducting research on the effect of Geniposide on Multiple Sclerosis through the S100b-RAGE Pathway at Shandong Normal University, with the research aiming to be completed on 16 December 2023. Figure 5 illustrates the effect of S100b at concentrations ranging from 0-1000 nM on the ratio of CD4+-IL-17+ T cells to CD4+ T cells through a statistical analysis. Results suggest that S100b has a significant effect on the proportion of CD4+ IL-17+ T cells at concentrations higher than 0 nM, supporting the hypothesis that S100b can promote differentiation of naive CD4+ T cells into Th17 cell subsets..

[Audio] Aqsa Bibi, a student at Shandong Normal University, is undertaking a study to examine the effects of Geniposide on Multiple Sclerosis through the S100b-RAGE Pathway. Guided by Prof. Dr. Guiwen Yang and Prof. Dr. Cui Lv, the project is slated for completion in December 2023. Aqsa has been carrying out an experimental plan to reach predicted outcomes. From March 2023 to October 2023, she conducted a literature review and Induction of MOG-EAE model of C57BL/6 mice to understand geniposide's mechanism via S100b-RAGE pathway modulation of CD4+ T cell differentiation. Research offered insight on the neuroprotective role of geniposide on the EAE model, as geniposide raised anti-inflammatory Treg cells and reduced pro-inflammatory Th17 and Th1 cells in the spleens of mice. Subsequently, from November 2023 to December 2023, S100b was evaluated to promote Th17 cell differentiation of naive CD4+ T cells at varying concentrations in vitro, with the results revealing that S100b had a direct, pro-inflammatory impact on CD4+ T cell differentiation by elevating Th17 subsets. Aqsa is also expected to look into the effects of geniposide on EAE model based of S100B-RAGE pathway for access to neuroinflammation, and evaluate geniposide's in vitro immunomodulation of CD4+ T cell replies and S100B-stimulated microglia activation in vitro. Upon completion of this project, she plans to write a paper to present her findings..

[image]. 谢谢！. 请各位专家老师批评指正.